The Scottish government has allocated £800,000 to deploy the Genedrive MT-RNR1 ID Kit across neonatal units to identify genetic risk for hearing loss caused by gentamicin antibiotic treatment. This complements a £1.4 million UK-wide study initiated in 2024 evaluating the test at multiple NHS neonatal centers. The adoption follows NICE recommendations endorsing the test for early detection of at-risk newborns, aiming to prevent permanent antibiotic-induced deafness through personalized antibiotic use.